Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms
The DOI matches its Crossref record.
Abstract
Some studies suggest that obsessive-compulsive symptoms may be common (7.8-46%) in schizophrenic patients and seem to be poorly responsive to drug therapy. Conventional neuroleptics are of limited value, but adjunctive anti-obsessive agents (clomipramine, fluvoxamine) may be an option. Although novel atypical antipsychotics (clozapine, risperidone) reportedly aggravate the obsessive-compulsive symptoms, a recent trial has shown that olanzapine did not induce new-onset obsessive-compulsive symptoms in schizophrenic patients. We report our experience with three schizophrenic patients with obsessive-compulsive symptoms who were unsuccessfully treated with various conventional neuroleptics in combination with anti-obsessive agents and subsequently showed resistance or intolerance to clozapine. All of them were switched to olanzapine (10-20 mg/ day). All patients demonstrated a significant improvement in both schizophrenic and obsessive-compulsive symptoms as measured by the Brief Psychiatric Rating Scale (BPRS) and the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Within 5-8 weeks of initiation of olanzapine, the BPRS scores of the three patient decreased by 53%, 51% and 48%, and the Y-BOCS scores by 68%, 73% and 85%. Olanzapine was well tolerated. These preliminary results suggest that olanzapine may be a therapeutic option in schizophrenic patients with obsessive-compulsive symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Marek, G. J., Carpenter, L. L., McDougle, C. J., & Price, L. H. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300057 · Cited by 275
“Obsessive–compulsive symptoms have been reported to be improved in schizophrenic patients treated with olanzapine (Poyurovsky et al, 2000).”
BackgroundFonseka, T. M., Richter, M. A., & Müller, D. J. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0510-8 · Cited by 93
The neuropsychology of the schizo-obsessive subtype of schizophrenia: a new analysis
Patel, D. D., Laws, K. R., Padhi, A., Farrow, J. M., Mukhopadhaya, K., Krishnaiah, R., & Fineberg, N. A. (2010) · Psychological Medicine · doi:10.1017/s0033291709991255 · Cited by 82
“…0.5 to 59.2% both in firstepisode and in chronic schizophrenia (Bland et al. 1987 ; Karno et al. 1988 ; Berman et al. 1995 ; Eisen et al. 1997 ; Poyurovsky et al. 1999a, 2000, 2003, 2006 ; Bermanzohn et al. 2000 ; Kruger et al. 2000 ; Niehaus et al. 2005 ; Mukhopadhaya et al. 2009) and for OCS…”
BackgroundInfluential
Metadata
- Authors
- Poyurovsky, M., Dorfman-Etrog, P., Hermesh, H., Munitz, H., Tollefson, G. D., & Weizman, A.
- Venue
- International Clinical Psychopharmacology
- Published
- 2000-05
- Volume
- 15
- Issue
- 3
- Pages
- 169-173
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W1964538442
- Cited by
- 49
- References
- 0
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms. https://app.cochat.ai/papers/10.1097/00004850-200015030-00006
- The paper
- Poyurovsky, M., Dorfman-Etrog, P., Hermesh, H., Munitz, H., Tollefson, G. D., & Weizman, A. (2000). Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200015030-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.